Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online.

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Human Mutation

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 10660343
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• The Impact of CYP3A4, CYP3A5, and ABCB1 Polymorphisms on Cyclosporine Concentration in Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation

  2025cites this paper
• New Insights into Prostate Cancer Susceptibility in European Caucasians: A Systematic Review and Meta-Analysis of CYP3A4 Pharmacogene

  2025cites this paper
• Association between CYP3A4, CYP3A5 and ABCB1 genotype and tacrolimus treatment outcomes among allogeneic HSCT patients.

  2024cites this paper
• Racial disparity in prostate cancer: an outlook in genetic and molecular landscape

  2024cites this paper
• Genetic association in CYP3A4 and CYP3A5 genes elevate the risk of prostate cancer

  2023cites this paper
• Developmental Pharmacogenetics of CYP2D6 in Chinese Children: Loratadine as a Substrate Drug

  2021cites this paper
• Association of CYP3A4*1B genotype with Cyclosporin A pharmacokinetics in renal transplant recipients: A meta-analysis.

  2018cites this paper
• The Influence of CYP3A4 Polymorphism in Sex Steroids as a Risk Factor for Breast Cancer

  2018cites this paper
• Genotype and Allele Frequency of CYP3A4 -392A>G in Turkish Patients with Major Depressive Disorder

  2017cites this paper
• Differenzialindikation von Opioiden in der Schmerztherapie

  2017cites this paper
• Pharmacogenomics and Laboratory Medicine

  2016cites this paper
• Prostate Cancer Risk in Relation to CYP3A4 and CYP3A5 Genotypes in the Bangladeshi Population

  2016cites this paper
• Pharmacogenomics Aspect of Immunosuppressant Therapy

  2016cites this paper
• Prostate Cancer Risk in Relation to CYP 3 A 4 and CYP 3 A 5 Genotypes in the Bangladeshi Population

  2016cites this paper
• Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase.

  2015cites this paper
• CYP2D6, CYP3A5, and CYP3A4 gene polymorphisms in Russian, Tatar, and Bashkir populations

  2015cites this paper
• Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review

  2014cites this paper
• Establishment and Characterization of a Highly Tumorigenic African American Prostate Cancer Cell Line, E006AA-hT

  2014cites this paper
• ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy

  2014cites this paper
• Race and Ethnicity in Cancer Therapy: What Have We Learned?

  2014cites this paper
• Cytochrome P450 pharmacogenetics in African populations

  2013cites this paper
• Pharmacogenetic analysis in the treatment of Hodgkin lymphoma

  2013cites this paper
• Screening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes

  2013cites this paper
• Ethnical disparities of prostate cancer predisposition: genetic polymorphisms in androgen-related genes.

  2013cites this paper
• Screening of Genetic Polymorphisms of CYP 3 A 4 and CYP 3 A 5 Genes

  2013cites this paper
• CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy.

  2013cites this paper
• Estudios de factores genéticos y ambientales que regulan el metabolismo de ebastina en voluntarios sanos

  2013cites this paper
• Evolutionary aspects and the implications for the treatment of infectious diseases

  2013cites this paper
• Pharmacokinetic and pharmacodynamic evaluation of linagliptin in African American patients with type 2 diabetes mellitus.

  2013cites this paper
• African variation at Cytochrome P450 genes

  2013cites this paper
• Allele and genotype frequencies of the polymorphic cytochrome P450 genes (CYP1A1, CYP3A4, CYP3A5, CYP2C9 and CYP2C19) in the Jordanian population

  2012cites this paper
• Pharmacogenetics of anti-estrogen treatment of breast cancer.

  2012cites this paper
• Pharmacogenetic Screening for Polymorphisms in Drug-Metabolizing Enzymes and Drug Transporters in a Dutch Population

  2012cites this paper
• Polymorphisms in androgen signaling pathway predisposing to prostate cancer.

  2012cites this paper
• Pharmacogenetics of Efavirenz response in Bantu-speaking South African HIV/AIDS patients

  2011cites this paper
• NEW APPROACHES IN UNDERSTANDING DRUG METABOLISM

  2011cites this paper
• CYP1A1 and CYP3A4 polymorphic variations in Delhi population of Northern India.

  2010cites this paper
• Shielded From the Real World: Perspectives on Internet Cancer Support Groups by Asian Americans

  2010cites this paper
• Pharmacogenomics of CYP3A: considerations for HIV treatment.

  2009cites this paper
• Biomarkers for Prostate Cancer Detection: Family-Based Linkage Analysis and Case–Control Association Studies

  2009cites this paper
• Molecular mechanisms involving prostate cancer racial disparity.

  2009cites this paper
• Genetic susceptibility to prostate cancer in men of African descent: implications for global disparities in incidence and outcomes.

  2008cites this paper
• Pharmacogenetics in Breast Cancer Therapy

  2008cites this paper
• CYP450 pharmacogenetics for personalizing cancer therapy.

  2008cites this paper
• Interindividual Variability of Methadone Response

  2008cites this paper
• Inherited Genetic Changes in Prostate Cancer

  2008cites this paper
• MOLECULAR GENETIC ANALYSIS OF HUMAN IMMUNODEFICIENCY VIRUS ANTIRETROVIRAL THERAPY RESPONSE IN SOUTH AFRICA - A PHARMACOGENETICS STUDY

  2007cites this paper
• Constitutional polymorphisms of prostate cancer: prognostic and diagnostic implications.

  2007cites this paper
• A Comparison of the Pharmacokinetics and Pharmacodynamics of Docetaxel between African-American and Caucasian Cancer Patients: CALGB 9871

  2007cites this paper
• Pharmacogenetically relevant polymorphisms in Portugal.

  2007cites this paper
• Pharmacogenetic screening of docetaxel, irinotecan and fluoropyrimidines in cancer therapy

  2006cites this paper
• Genetic Polymorphisms of Drug-Metabolising Enzymes and Drug Transporters in the Chemotherapeutic Treatment of Cancer

  2006cites this paper
• Prostate cancer detection strategies

  2006cites this paper
• Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression.

  2006cites this paper
• Prostate cancer detection strategies

  2006cites this paper
• Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population.

  2006cites this paper
• Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects

  2006cites this paper
• Impact of CYP3A5 Genetic Polymorphism on the Biotransformation of Drugs and Environmental Toxins

  2006cites this paper
• An Interethnic Comparison of Polymorphisms of the Genes Encoding Drug-Metabolizing Enzymes and Drug Transporters: Experience in Singapore

  2005influential citation
• CYP3A43 Pro340Ala Polymorphism and Prostate Cancer Risk in African Americans and Caucasians

  2005cites this paper
• Cancer treatment and pharmacogenetics of cytochrome P450 enzymes

  2005influential citation
• Analysis of restriction fragment length polymorphism of cytochrome P450 3A43 gene and evaluation of the incidence of CYP3A43*1B allele in europeoid residents of West Siberia

  2005cites this paper
• EFFECT OF CYP2D6*10 ALLELE ON THE PHARMACOKINETICS OF LORATADINE IN CHINESE SUBJECTS

  2005influential citation
• Association study of four activity SNPs of CYP3A4 with the precocious puberty in Chinese girls.

  2005cites this paper
• Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip.

  2005cites this paper
• Biomarkers for the detection and prognosis of prostate cancer

  2005cites this paper
• Drug-metabolizing enzyme polymorphisms predict clinical outcome in a node-positive breast cancer cohort.

  2005cites this paper
• Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.

  2005cites this paper
• Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer.

  2005cites this paper
• CYP3A4 genetic variant and disease-free survival among white and black men after radical prostatectomy.

  2004cites this paper
• CYP3A4 polymorphisms--potential risk factors for breast and prostate cancer: a HuGE review.

  2004cites this paper
• Cytochrome P450 3A and their regulation

  2004cites this paper
• Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population

  2004cites this paper
• Genetic polymorphisms and prostate cancer risk

  2004cites this paper
• Factors Affecting Cytochrome P-450 3A Activity in Cancer Patients

  2004cites this paper
• Recent advances in pharmacogenetic approaches to anticancer drug development

  2004cites this paper
• Implications of Cytochrome P450 Genetic Polymorphisms on the Toxicity of Antitumor Agents

  2004cites this paper
• Implications of cytochrome P450 genetic polymorphisms on the toxicity of antitumor agents.

  2004influential citation
• Detection of CYP3A4*1B and CYP3A4*2 polymorphisms by RFLP. Distribution frequencies in a Mexican population

  2004cites this paper
• The Special Problems of Prostate Cancer Among African Americans

  2004cites this paper
• LC-MS/MS analysis of dextromethorphan metabolism in human saliva and urine to determine CYP2D6 phenotype and individual variability in N-demethylation and glucuronidation.

  2004cites this paper
• The epidemiology of prostate cancer.

  2003cites this paper
• CYP3A4 and VDR gene polymorphisms and the risk of prostate cancer in men with benign prostate hyperplasia

  2003cites this paper
• Urinary 6β-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals

  2003cites this paper
• Survival variability by race and ethnicity in childhood acute lymphoblastic leukemia.

  2003cites this paper
• Epidemiological investigation of prostate cancer.

  2003cites this paper
• Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

  2003cites this paper
• Increased transcriptional activity of the CYP3A4*1B promoter variant

  2003cites this paper
• Chapter 10 – Prostate Cancer Prevention: Strategies and Realities

  2003cites this paper
• Alleles in a Native African Population

  2003cites this paper
• The role of genetic polymorphisms in environmental health.

  2003cites this paper
• CYP3A4*1B and NAT2*14 Alleles in a Native African Population

  2003influential citation
• The CYP 3 A 4 * 1 B Variant Is Related to the Onset of Puberty , A Known Risk Factor for the Development of Breast Cancer 1

  2003cites this paper
• The CYP3A4*1B variant is related to the onset of puberty, a known risk factor for the development of breast cancer.

  2003cites this paper
• The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer.

  2002cites this paper
• Modeling of human hepatic CYP3A4 enzyme kinetics, protein, and mRNA indicates deviation from log-normal distribution in CYP3A4 gene expression

  2002cites this paper
• Genetic contribution to variable human CYP3A-mediated metabolism.

  2002cites this paper
• Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species differences and interindividual variation in man

  2002cites this paper
• CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification?

  2002influential citation
• Racial and ethnic differences in survival of children with acute lymphoblastic leukemia.

  2002cites this paper